EGFR and neoplasm: To demonstrate feasibility beyond exome data, we next evaluated these same metrics in a targeted 5-gene panel applied to a cell-free DNA sequencing library generated from a healthy blood donor and sequenced to >10,000X coverage[17] To simulate concentrations of tumor-derived fragments typically encountered in cancer patients, we introduced EGFR amplifications at frequencies of 100, 10, 1, 0.1, and 0.01%.